APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Angiogenesis Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Angiogenesis Inhibitors Market Analysis and Forecast 2026-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchCancer Angiogenesis Inhibitors Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Angiogenesis Inhibitors Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Cancer Angiogenesis Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Angiogenesis Inhibitors Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Angiogenesis Inhibitors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Cancer Angiogenesis Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cancer Angiogenesis Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Angiogenesis Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Angiogenesis Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Angiogenesis Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Cancer Angiogenesis Inhibitors include Novartis, Neumedicines, Marsala Biotech, Mabtech, Levolta Pharmaceuticals, Kyowa Hakko Kirin, Intas Pharmaceuticals, ImClone Systems and Hetero Drugs, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cancer Angiogenesis Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Angiogenesis Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Cancer Angiogenesis Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Angiogenesis Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Angiogenesis Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Cancer Angiogenesis Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Cancer Angiogenesis Inhibitors Segment by Company

Novartis

Neumedicines

Marsala Biotech

Mabtech

Levolta Pharmaceuticals

Kyowa Hakko Kirin

Intas Pharmaceuticals

ImClone Systems

Hetero Drugs

Genexine

Genentech

Fuji Film Kyowa Kirin Biologics

Five Prime Therapeutics

Cancer Angiogenesis Inhibitors Segment by Type

Oncogene Targeted Therapy

Matrix Degrading & Remodeling Targeted Therapy

VEGF Targeted Therapy

FGF Targeted Therapies

Others

Cancer Angiogenesis Inhibitors Segment by Application

Ocular Neovascularization

Interferon Alpha-2α

Cancer

Cancer Angiogenesis Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Angiogenesis Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Angiogenesis Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Angiogenesis Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Cancer Angiogenesis Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Cancer Angiogenesis Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Angiogenesis Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oncogene Targeted Therapy Major Manufacturers Table 3. Matrix Degrading & Remodeling Targeted Therapy Major Manufacturers Table 4. VEGF Targeted Therapy Major Manufacturers Table 5. FGF Targeted Therapies Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Ocular Neovascularization Major Manufacturers Table 9. Interferon Alpha-2α Major Manufacturers Table 10. Cancer Major Manufacturers Table 11. Cancer Angiogenesis Inhibitors Industry Trends Table 12. Cancer Angiogenesis Inhibitors Industry Drivers Table 13. Cancer Angiogenesis Inhibitors Industry Opportunities and Challenges Table 14. Cancer Angiogenesis Inhibitors Industry Restraints Table 15. Global Cancer Angiogenesis Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Cancer Angiogenesis Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Cancer Angiogenesis Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2021-2026) Table 19. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2027-2032) Table 20. Global Cancer Angiogenesis Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 21. Global Cancer Angiogenesis Inhibitors Sales by Region (2021-2026) & (k units) Table 22. Global Cancer Angiogenesis Inhibitors Sales by Region (2027-2032) & (k units) Table 23. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2021-2026) Table 24. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2027-2032) Table 25. Global Cancer Angiogenesis Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Cancer Angiogenesis Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Cancer Angiogenesis Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 29. Global Cancer Angiogenesis Inhibitors Sales Price (US$/unit) of Manufacturers (2021-2026) Table 30. Global Cancer Angiogenesis Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Cancer Angiogenesis Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Cancer Angiogenesis Inhibitors Manufacturers, Product Type & Application Table 33. Global Cancer Angiogenesis Inhibitors Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Cancer Angiogenesis Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Cancer Angiogenesis Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Cancer Angiogenesis Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Cancer Angiogenesis Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2021-2026) Table 40. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2027-2032) Table 41. Global Cancer Angiogenesis Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 42. Global Cancer Angiogenesis Inhibitors Sales by Type (2021-2026) & (k units) Table 43. Global Cancer Angiogenesis Inhibitors Sales by Type (2027-2032) & (k units) Table 44. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2021-2026) Table 45. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2027-2032) Table 46. Global Cancer Angiogenesis Inhibitors Price by Type (2021-2026) & (US$/unit) Table 47. Global Cancer Angiogenesis Inhibitors Price by Type (2027-2032) & (US$/unit) Table 48. Global Cancer Angiogenesis Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Cancer Angiogenesis Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Cancer Angiogenesis Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2021-2026) Table 52. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2027-2032) Table 53. Global Cancer Angiogenesis Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 54. Global Cancer Angiogenesis Inhibitors Sales by Application (2021-2026) & (k units) Table 55. Global Cancer Angiogenesis Inhibitors Sales by Application (2027-2032) & (k units) Table 56. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2021-2026) Table 57. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2027-2032) Table 58. Global Cancer Angiogenesis Inhibitors Price by Application (2021-2026) & (US$/unit) Table 59. Global Cancer Angiogenesis Inhibitors Price by Application (2027-2032) & (US$/unit) Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 63. Novartis Cancer Angiogenesis Inhibitors Product Portfolio Table 64. Novartis Recent Development Table 65. Neumedicines Company Information Table 66. Neumedicines Business Overview Table 67. Neumedicines Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Neumedicines Cancer Angiogenesis Inhibitors Product Portfolio Table 69. Neumedicines Recent Development Table 70. Marsala Biotech Company Information Table 71. Marsala Biotech Business Overview Table 72. Marsala Biotech Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolio Table 74. Marsala Biotech Recent Development Table 75. Mabtech Company Information Table 76. Mabtech Business Overview Table 77. Mabtech Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Mabtech Cancer Angiogenesis Inhibitors Product Portfolio Table 79. Mabtech Recent Development Table 80. Levolta Pharmaceuticals Company Information Table 81. Levolta Pharmaceuticals Business Overview Table 82. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio Table 84. Levolta Pharmaceuticals Recent Development Table 85. Kyowa Hakko Kirin Company Information Table 86. Kyowa Hakko Kirin Business Overview Table 87. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolio Table 89. Kyowa Hakko Kirin Recent Development Table 90. Intas Pharmaceuticals Company Information Table 91. Intas Pharmaceuticals Business Overview Table 92. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio Table 94. Intas Pharmaceuticals Recent Development Table 95. ImClone Systems Company Information Table 96. ImClone Systems Business Overview Table 97. ImClone Systems Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolio Table 99. ImClone Systems Recent Development Table 100. Hetero Drugs Company Information Table 101. Hetero Drugs Business Overview Table 102. Hetero Drugs Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolio Table 104. Hetero Drugs Recent Development Table 105. Genexine Company Information Table 106. Genexine Business Overview Table 107. Genexine Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Genexine Cancer Angiogenesis Inhibitors Product Portfolio Table 109. Genexine Recent Development Table 110. Genentech Company Information Table 111. Genentech Business Overview Table 112. Genentech Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Genentech Cancer Angiogenesis Inhibitors Product Portfolio Table 114. Genentech Recent Development Table 115. Fuji Film Kyowa Kirin Biologics Company Information Table 116. Fuji Film Kyowa Kirin Biologics Business Overview Table 117. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolio Table 119. Fuji Film Kyowa Kirin Biologics Recent Development Table 120. Five Prime Therapeutics Company Information Table 121. Five Prime Therapeutics Business Overview Table 122. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolio Table 124. Five Prime Therapeutics Recent Development Table 125. North America Cancer Angiogenesis Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 126. North America Cancer Angiogenesis Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 127. North America Cancer Angiogenesis Inhibitors Sales by Type (2021-2026) & (k units) Table 128. North America Cancer Angiogenesis Inhibitors Sales by Type (2027-2032) & (k units) Table 129. North America Cancer Angiogenesis Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 130. North America Cancer Angiogenesis Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 131. North America Cancer Angiogenesis Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 132. North America Cancer Angiogenesis Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 133. North America Cancer Angiogenesis Inhibitors Sales by Application (2021-2026) & (k units) Table 134. North America Cancer Angiogenesis Inhibitors Sales by Application (2027-2032) & (k units) Table 135. North America Cancer Angiogenesis Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 136. North America Cancer Angiogenesis Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 137. North America Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. North America Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 139. North America Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 140. North America Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 141. North America Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 142. North America Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 143. North America Cancer Angiogenesis Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 144. North America Cancer Angiogenesis Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 145. United States Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 146. Canada Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 147. Mexico Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 148. Europe Cancer Angiogenesis Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 149. Europe Cancer Angiogenesis Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 150. Europe Cancer Angiogenesis Inhibitors Sales by Type (2021-2026) & (k units) Table 151. Europe Cancer Angiogenesis Inhibitors Sales by Type (2027-2032) & (k units) Table 152. Europe Cancer Angiogenesis Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 153. Europe Cancer Angiogenesis Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 154. Europe Cancer Angiogenesis Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 155. Europe Cancer Angiogenesis Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 156. Europe Cancer Angiogenesis Inhibitors Sales by Application (2021-2026) & (k units) Table 157. Europe Cancer Angiogenesis Inhibitors Sales by Application (2027-2032) & (k units) Table 158. Europe Cancer Angiogenesis Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 159. Europe Cancer Angiogenesis Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 160. Europe Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Europe Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 162. Europe Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 163. Europe Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 164. Europe Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 165. Europe Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 166. Europe Cancer Angiogenesis Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 167. Europe Cancer Angiogenesis Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 168. Germany Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 169. France Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 170. U.K. Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 171. Italy Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 172. Russia Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 173. Spain Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 174. Netherlands Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 175. Switzerland Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 176. Sweden Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 177. Poland Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 178. China Cancer Angiogenesis Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 179. China Cancer Angiogenesis Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 180. China Cancer Angiogenesis Inhibitors Sales by Type (2021-2026) & (k units) Table 181. China Cancer Angiogenesis Inhibitors Sales by Type (2027-2032) & (k units) Table 182. China Cancer Angiogenesis Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 183. China Cancer Angiogenesis Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 184. China Cancer Angiogenesis Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 185. China Cancer Angiogenesis Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 186. China Cancer Angiogenesis Inhibitors Sales by Application (2021-2026) & (k units) Table 187. China Cancer Angiogenesis Inhibitors Sales by Application (2027-2032) & (k units) Table 188. China Cancer Angiogenesis Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 189. China Cancer Angiogenesis Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 190. Asia Cancer Angiogenesis Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 191. Asia Cancer Angiogenesis Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 192. Asia Cancer Angiogenesis Inhibitors Sales by Type (2021-2026) & (k units) Table 193. Asia Cancer Angiogenesis Inhibitors Sales by Type (2027-2032) & (k units) Table 194. Asia Cancer Angiogenesis Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 195. Asia Cancer Angiogenesis Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 196. Asia Cancer Angiogenesis Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 197. Asia Cancer Angiogenesis Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 198. Asia Cancer Angiogenesis Inhibitors Sales by Application (2021-2026) & (k units) Table 199. Asia Cancer Angiogenesis Inhibitors Sales by Application (2027-2032) & (k units) Table 200. Asia Cancer Angiogenesis Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 201. Asia Cancer Angiogenesis Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 202. Asia Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 203. Asia Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 204. Asia Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 205. Asia Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 206. Asia Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 207. Asia Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 208. Asia Cancer Angiogenesis Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 209. Asia Cancer Angiogenesis Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 210. Japan Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 211. South Korea Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 212. India Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 213. Australia Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 214. Taiwan Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 215. Southeast Asia Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 216. SAMEA Cancer Angiogenesis Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 217. SAMEA Cancer Angiogenesis Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 218. SAMEA Cancer Angiogenesis Inhibitors Sales by Type (2021-2026) & (k units) Table 219. SAMEA Cancer Angiogenesis Inhibitors Sales by Type (2027-2032) & (k units) Table 220. SAMEA Cancer Angiogenesis Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 221. SAMEA Cancer Angiogenesis Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 222. SAMEA Cancer Angiogenesis Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 223. SAMEA Cancer Angiogenesis Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 224. SAMEA Cancer Angiogenesis Inhibitors Sales by Application (2021-2026) & (k units) Table 225. SAMEA Cancer Angiogenesis Inhibitors Sales by Application (2027-2032) & (k units) Table 226. SAMEA Cancer Angiogenesis Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 227. SAMEA Cancer Angiogenesis Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 228. SAMEA Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 229. SAMEA Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 230. SAMEA Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 231. SAMEA Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 232. SAMEA Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 233. SAMEA Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 234. SAMEA Cancer Angiogenesis Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 235. SAMEA Cancer Angiogenesis Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 236. Brazil Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 237. Argentina Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 238. Chile Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 239. Colombia Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 240. Peru Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 241. Saudi Arabia Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 242. Israel Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 243. UAE Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 244. Turkey Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 245. Iran Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 246. Egypt Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Table 247. Key Raw Materials Table 248. Raw Materials Key Suppliers Table 249. Cancer Angiogenesis Inhibitors Distributors List Table 250. Cancer Angiogenesis Inhibitors Customers List Table 251. Research Programs/Design for This Report Table 252. Authors List of This Report Table 253. Secondary Sources Table 254. Primary Sources List of Figures Figure 1. Cancer Angiogenesis Inhibitors Image Figure 2. Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Angiogenesis Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oncogene Targeted Therapy Image Figure 5. Matrix Degrading & Remodeling Targeted Therapy Image Figure 6. VEGF Targeted Therapy Image Figure 7. FGF Targeted Therapies Image Figure 8. Others Image Figure 9. Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Cancer Angiogenesis Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 11. Ocular Neovascularization Image Figure 12. Interferon Alpha-2α Image Figure 13. Cancer Image Figure 14. Global Cancer Angiogenesis Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Figure 16. Global Cancer Angiogenesis Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2021-2032) Figure 19. Global Cancer Angiogenesis Inhibitors Sales (2021-2032) & (k units) Figure 20. Global Cancer Angiogenesis Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 21. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Cancer Angiogenesis Inhibitors Sales YoY (2021-2032) & (k units) Figure 23. Europe Cancer Angiogenesis Inhibitors Sales YoY (2021-2032) & (k units) Figure 24. China Cancer Angiogenesis Inhibitors Sales YoY (2021-2032) & (k units) Figure 25. Asia (Excluding China) Cancer Angiogenesis Inhibitors Sales YoY (2021-2032) & (k units) Figure 26. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales YoY (2021-2032) & (k units) Figure 27. Global Cancer Angiogenesis Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Cancer Angiogenesis Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Cancer Angiogenesis Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2021-2032) Figure 33. Global Cancer Angiogenesis Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 34. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2021-2032) Figure 36. Global Cancer Angiogenesis Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2021-2032) Figure 39. Global Cancer Angiogenesis Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 40. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2021-2032) Figure 42. North America Cancer Angiogenesis Inhibitors Revenue Share by Type (2021-2032) Figure 43. North America Cancer Angiogenesis Inhibitors Sales Share by Type (2021-2032) Figure 44. North America Cancer Angiogenesis Inhibitors Revenue Share by Application (2021-2032) Figure 45. North America Cancer Angiogenesis Inhibitors Sales Share by Application (2021-2032) Figure 46. North America Cancer Angiogenesis Inhibitors Revenue Share by Country (2021-2032) Figure 47. North America Cancer Angiogenesis Inhibitors Sales Share by Country (2021-2032) Figure 48. Europe Cancer Angiogenesis Inhibitors Revenue Share by Type (2021-2032) Figure 49. Europe Cancer Angiogenesis Inhibitors Sales Share by Type (2021-2032) Figure 50. Europe Cancer Angiogenesis Inhibitors Revenue Share by Application (2021-2032) Figure 51. Europe Cancer Angiogenesis Inhibitors Sales Share by Application (2021-2032) Figure 52. Europe Cancer Angiogenesis Inhibitors Revenue Share by Country (2021-2032) Figure 53. Europe Cancer Angiogenesis Inhibitors Sales Share by Country (2021-2032) Figure 54. China Cancer Angiogenesis Inhibitors Revenue Share by Type (2021-2032) Figure 55. China Cancer Angiogenesis Inhibitors Sales Share by Type (2021-2032) Figure 56. China Cancer Angiogenesis Inhibitors Revenue Share by Application (2021-2032) Figure 57. China Cancer Angiogenesis Inhibitors Sales Share by Application (2021-2032) Figure 58. Asia Cancer Angiogenesis Inhibitors Revenue Share by Type (2021-2032) Figure 59. Asia Cancer Angiogenesis Inhibitors Sales Share by Type (2021-2032) Figure 60. Asia Cancer Angiogenesis Inhibitors Revenue Share by Application (2021-2032) Figure 61. Asia Cancer Angiogenesis Inhibitors Sales Share by Application (2021-2032) Figure 62. Asia Cancer Angiogenesis Inhibitors Revenue Share by Country (2021-2032) Figure 63. Asia Cancer Angiogenesis Inhibitors Sales Share by Country (2021-2032) Figure 64. SAMEA Cancer Angiogenesis Inhibitors Revenue Share by Type (2021-2032) Figure 65. SAMEA Cancer Angiogenesis Inhibitors Sales Share by Type (2021-2032) Figure 66. SAMEA Cancer Angiogenesis Inhibitors Revenue Share by Application (2021-2032) Figure 67. SAMEA Cancer Angiogenesis Inhibitors Sales Share by Application (2021-2032) Figure 68. SAMEA Cancer Angiogenesis Inhibitors Revenue Share by Country (2021-2032) Figure 69. SAMEA Cancer Angiogenesis Inhibitors Sales Share by Country (2021-2032) Figure 70. Cancer Angiogenesis Inhibitors Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Cancer Angiogenesis Inhibitors Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Oncogene Targeted Therapy
  • Matrix Degrading & Remodeling Targeted Therapy
  • VEGF Targeted Therapy
  • FGF Targeted Therapies
  • Others
Applications
  • Ocular Neovascularization
  • Interferon Alpha-2α
  • Cancer
Companies covered
  • Novartis
  • Neumedicines
  • Marsala Biotech
  • Mabtech
  • Levolta Pharmaceuticals
  • Kyowa Hakko Kirin
  • Intas Pharmaceuticals
  • ImClone Systems
  • Hetero Drugs
  • Genexine
  • Genentech
  • Fuji Film Kyowa Kirin Biologics
  • Five Prime Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Angiogenesis Inhibitors Market by Type
  3. 1.2.1 Global Cancer Angiogenesis Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oncogene Targeted Therapy
  5. 1.2.3 Matrix Degrading & Remodeling Targeted Therapy
  6. 1.2.4 VEGF Targeted Therapy
  7. 1.2.5 FGF Targeted Therapies
  8. 1.2.6 Others
  9. 1.3 Cancer Angiogenesis Inhibitors Market by Application
  10. 1.3.1 Global Cancer Angiogenesis Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Ocular Neovascularization
  12. 1.3.3 Interferon Alpha-2α
  13. 1.3.4 Cancer
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Cancer Angiogenesis Inhibitors Market Dynamics
  1. 2.1 Cancer Angiogenesis Inhibitors Industry Trends
  2. 2.2 Cancer Angiogenesis Inhibitors Industry Drivers
  3. 2.3 Cancer Angiogenesis Inhibitors Industry Opportunities and Challenges
  4. 2.4 Cancer Angiogenesis Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Cancer Angiogenesis Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Cancer Angiogenesis Inhibitors Revenue by Region
  3. 3.2.1 Global Cancer Angiogenesis Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Angiogenesis Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global Cancer Angiogenesis Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Cancer Angiogenesis Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Cancer Angiogenesis Inhibitors Sales by Region
  9. 3.4.1 Global Cancer Angiogenesis Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Cancer Angiogenesis Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global Cancer Angiogenesis Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Cancer Angiogenesis Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global Cancer Angiogenesis Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Cancer Angiogenesis Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Angiogenesis Inhibitors Sales by Manufacturers
  6. 4.2.1 Global Cancer Angiogenesis Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Cancer Angiogenesis Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Cancer Angiogenesis Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Cancer Angiogenesis Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Cancer Angiogenesis Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Cancer Angiogenesis Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Cancer Angiogenesis Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global Cancer Angiogenesis Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Cancer Angiogenesis Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 Cancer Angiogenesis Inhibitors Tier 1, Tier 2, and Tier 3
5 Cancer Angiogenesis Inhibitors Market by Type
  1. 5.1 Global Cancer Angiogenesis Inhibitors Revenue by Type
  2. 5.1.1 Global Cancer Angiogenesis Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Cancer Angiogenesis Inhibitors Sales by Type
  6. 5.2.1 Global Cancer Angiogenesis Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Angiogenesis Inhibitors Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global Cancer Angiogenesis Inhibitors Price by Type
6 Cancer Angiogenesis Inhibitors Market by Application
  1. 6.1 Global Cancer Angiogenesis Inhibitors Revenue by Application
  2. 6.1.1 Global Cancer Angiogenesis Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Cancer Angiogenesis Inhibitors Sales by Application
  6. 6.2.1 Global Cancer Angiogenesis Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Cancer Angiogenesis Inhibitors Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global Cancer Angiogenesis Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Cancer Angiogenesis Inhibitors Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Neumedicines
  8. 7.2.1 Neumedicines Company Information
  9. 7.2.2 Neumedicines Business Overview
  10. 7.2.3 Neumedicines Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Neumedicines Cancer Angiogenesis Inhibitors Product Portfolio
  12. 7.2.5 Neumedicines Recent Developments
  13. 7.3 Marsala Biotech
  14. 7.3.1 Marsala Biotech Company Information
  15. 7.3.2 Marsala Biotech Business Overview
  16. 7.3.3 Marsala Biotech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolio
  18. 7.3.5 Marsala Biotech Recent Developments
  19. 7.4 Mabtech
  20. 7.4.1 Mabtech Company Information
  21. 7.4.2 Mabtech Business Overview
  22. 7.4.3 Mabtech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Mabtech Cancer Angiogenesis Inhibitors Product Portfolio
  24. 7.4.5 Mabtech Recent Developments
  25. 7.5 Levolta Pharmaceuticals
  26. 7.5.1 Levolta Pharmaceuticals Company Information
  27. 7.5.2 Levolta Pharmaceuticals Business Overview
  28. 7.5.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
  30. 7.5.5 Levolta Pharmaceuticals Recent Developments
  31. 7.6 Kyowa Hakko Kirin
  32. 7.6.1 Kyowa Hakko Kirin Company Information
  33. 7.6.2 Kyowa Hakko Kirin Business Overview
  34. 7.6.3 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolio
  36. 7.6.5 Kyowa Hakko Kirin Recent Developments
  37. 7.7 Intas Pharmaceuticals
  38. 7.7.1 Intas Pharmaceuticals Company Information
  39. 7.7.2 Intas Pharmaceuticals Business Overview
  40. 7.7.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
  42. 7.7.5 Intas Pharmaceuticals Recent Developments
  43. 7.8 ImClone Systems
  44. 7.8.1 ImClone Systems Company Information
  45. 7.8.2 ImClone Systems Business Overview
  46. 7.8.3 ImClone Systems Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolio
  48. 7.8.5 ImClone Systems Recent Developments
  49. 7.9 Hetero Drugs
  50. 7.9.1 Hetero Drugs Company Information
  51. 7.9.2 Hetero Drugs Business Overview
  52. 7.9.3 Hetero Drugs Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolio
  54. 7.9.5 Hetero Drugs Recent Developments
  55. 7.10 Genexine
  56. 7.10.1 Genexine Company Information
  57. 7.10.2 Genexine Business Overview
  58. 7.10.3 Genexine Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Genexine Cancer Angiogenesis Inhibitors Product Portfolio
  60. 7.10.5 Genexine Recent Developments
  61. 7.11 Genentech
  62. 7.11.1 Genentech Company Information
  63. 7.11.2 Genentech Business Overview
  64. 7.11.3 Genentech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Genentech Cancer Angiogenesis Inhibitors Product Portfolio
  66. 7.11.5 Genentech Recent Developments
  67. 7.12 Fuji Film Kyowa Kirin Biologics
  68. 7.12.1 Fuji Film Kyowa Kirin Biologics Company Information
  69. 7.12.2 Fuji Film Kyowa Kirin Biologics Business Overview
  70. 7.12.3 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolio
  72. 7.12.5 Fuji Film Kyowa Kirin Biologics Recent Developments
  73. 7.13 Five Prime Therapeutics
  74. 7.13.1 Five Prime Therapeutics Company Information
  75. 7.13.2 Five Prime Therapeutics Business Overview
  76. 7.13.3 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolio
  78. 7.13.5 Five Prime Therapeutics Recent Developments
8 North America
  1. 8.1 North America Cancer Angiogenesis Inhibitors Market Size by Type
  2. 8.1.1 North America Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America Cancer Angiogenesis Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America Cancer Angiogenesis Inhibitors Price by Type (2021-2032)
  5. 8.2 North America Cancer Angiogenesis Inhibitors Market Size by Application
  6. 8.2.1 North America Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America Cancer Angiogenesis Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America Cancer Angiogenesis Inhibitors Price by Application (2021-2032)
  9. 8.3 North America Cancer Angiogenesis Inhibitors Market Size by Country
  10. 8.3.1 North America Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Cancer Angiogenesis Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Cancer Angiogenesis Inhibitors Market Size by Type
  2. 9.1.1 Europe Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe Cancer Angiogenesis Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe Cancer Angiogenesis Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe Cancer Angiogenesis Inhibitors Market Size by Application
  6. 9.2.1 Europe Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe Cancer Angiogenesis Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe Cancer Angiogenesis Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe Cancer Angiogenesis Inhibitors Market Size by Country
  10. 9.3.1 Europe Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Cancer Angiogenesis Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Cancer Angiogenesis Inhibitors Market Size by Type
  2. 10.1.1 China Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China Cancer Angiogenesis Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China Cancer Angiogenesis Inhibitors Price by Type (2021-2032)
  5. 10.2 China Cancer Angiogenesis Inhibitors Market Size by Application
  6. 10.2.1 China Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China Cancer Angiogenesis Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China Cancer Angiogenesis Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Angiogenesis Inhibitors Market Size by Type
  2. 11.1.1 Asia Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia Cancer Angiogenesis Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia Cancer Angiogenesis Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia Cancer Angiogenesis Inhibitors Market Size by Application
  6. 11.2.1 Asia Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia Cancer Angiogenesis Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia Cancer Angiogenesis Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia Cancer Angiogenesis Inhibitors Market Size by Country
  10. 11.3.1 Asia Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Cancer Angiogenesis Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Angiogenesis Inhibitors Market Size by Type
  2. 12.1.1 SAMEA Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Cancer Angiogenesis Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Cancer Angiogenesis Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA Cancer Angiogenesis Inhibitors Market Size by Application
  6. 12.2.1 SAMEA Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Cancer Angiogenesis Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Cancer Angiogenesis Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA Cancer Angiogenesis Inhibitors Market Size by Country
  10. 12.3.1 SAMEA Cancer Angiogenesis Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Cancer Angiogenesis Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Cancer Angiogenesis Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Cancer Angiogenesis Inhibitors Value Chain Analysis
  2. 13.1.1 Cancer Angiogenesis Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Cancer Angiogenesis Inhibitors Production Mode & Process
  6. 13.2 Cancer Angiogenesis Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Cancer Angiogenesis Inhibitors Distributors
  9. 13.2.3 Cancer Angiogenesis Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst